Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIAT for Resectable Pancreatic Adenocarcinoma at High Risk of Fistula
NCT05116072Phase 2Recruiting
- Sponsor
- CHU de Lille
- Start
- Feb 2022
- Primary completion
- Feb 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous islets of Langerhans in exocrine pancreatic insufficiency (EPI), sponsored by CHU de Lille. Started Feb 2022; status: recruiting.
02
Drugs
autologous islets of Langerhans
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT05116072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116072.